Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
Open Access
- 17 February 2025
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Abstract
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.Keywords
All Related Versions
Funding Information
- Howard Hughes Medical Institute
- Ludwig Family Foundation
- Oncology Core CA (06973)
- Sol Goldman Charitable Trust
- NCI Cancer Center Support Grant (P30 CA006973)
- National Cancer Institute (K08CA270403)
- Leukemia and Lymphoma Society (Translation Research Program Award)
- American Society of Hematology (Scholar Award)
- Swim Across America (Translational Cancer Research Award)
This publication has 88 references indexed in Scilit:
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunityCell, 2021
- Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayCancer, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer CareJAMA Oncology, 2018
- Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivoBiochemical and Biophysical Research Communications, 2017
- ggplot22016
- Identification of pyrimidine derivatives as hSMG-1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2012
- In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native KinasesChemistry & Biology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase i study of emetine hydrochloride (nsc 33669) in solid tumorsCancer, 1973